76 related articles for article (PubMed ID: 19930022)
41. Correlates of susceptibility to hepatitis B among people who inject drugs in Sydney, Australia.
Deacon RM; Topp L; Wand H; Day CA; Rodgers C; Haber PS; van Beek I; Maher L
J Urban Health; 2012 Oct; 89(5):769-78. PubMed ID: 22684422
[TBL] [Abstract][Full Text] [Related]
42. A window of opportunity: declining rates of hepatitis B virus infection among injection drug users in Rio de Janeiro, and prospects for targeted hepatitis B vaccination.
Oliveira SA; Hacker MA; Oliveira ML; Yoshida CF; Telles PR; Bastos FI
Rev Panam Salud Publica; 2005; 18(4-5):271-7. PubMed ID: 16354424
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis B virus infection and vaccination status of high risk people in Sydney: 1982 and 1991.
Anderson B; Bodsworth NJ; Rohrsheim RA; Donovan BJ
Med J Aust; 1994 Sep; 161(6):368-71. PubMed ID: 8090114
[TBL] [Abstract][Full Text] [Related]
44. Vaccination induced immunity to the hepatitis B virus among high-risk groups in Glasgow 1993-2001: evaluating the effectiveness of the United Kingdom's selective immunisation policy.
Roy KM; Goldberg DJ; Wilson K; Cameron SO
Scott Med J; 2008 Nov; 53(4):13-7. PubMed ID: 19051658
[TBL] [Abstract][Full Text] [Related]
45. Poor hepatitis B vaccine coverage in injecting drug users: England, 1995 and 1996.
Lamagni TL; Davison KL; Hope VD; Luutu JW; Newham JA; Parry JV; Gill ON
Commun Dis Public Health; 1999 Sep; 2(3):174-7. PubMed ID: 10491870
[TBL] [Abstract][Full Text] [Related]
46. Acceptance and completion of hepatitis B vaccination among drug users in New York City.
Ompad DC; Galea S; Wu Y; Fuller CM; Latka M; Koblin B; Vlahov D
Commun Dis Public Health; 2004 Dec; 7(4):294-300. PubMed ID: 15779793
[TBL] [Abstract][Full Text] [Related]
47. Accuracy of perceptions of hepatitis B and C status. Injecting drug users need vaccination against hepatitis B.
Ramsay ME; Balogun MA; Teo CG; Mortimer PP
BMJ; 2000 Feb; 320(7233):512; author reply 513. PubMed ID: 10678875
[No Abstract] [Full Text] [Related]
48. The validity of injecting drug users' self-reports about sexually transmitted diseases: a comparison of survey and serological data.
Kleyn J; Schwebke J; Holmes KK
Addiction; 1993 May; 88(5):673-80. PubMed ID: 8518718
[TBL] [Abstract][Full Text] [Related]
49. Failure to vaccinate current injecting drug users against hepatitis B in England and Wales.
Lamagni TL; Hope VD; Davison KL; Parry JV; Gill ON
Commun Dis Public Health; 2001 Mar; 4(1):71-2. PubMed ID: 11467026
[TBL] [Abstract][Full Text] [Related]
50. Self-reported patient history to assess hepatitis B virus serological status during a large screening campaign.
Boyd A; Gozlan J; Carrat F; Rougier H; Girard PM; Lacombe K; Bottero J
Epidemiol Infect; 2018 Sep; 147():e16. PubMed ID: 30264683
[TBL] [Abstract][Full Text] [Related]
51. Physician recognition of active drug use in HIV-infected patients is lower than validity of patient's self-reported drug use.
Messiah A; Loundou AD; Maslin V; Lacarelle B; Moatti JP;
J Pain Symptom Manage; 2001 Feb; 21(2):103-12. PubMed ID: 11302118
[TBL] [Abstract][Full Text] [Related]
52. Self-Test On Infection Control.
Postgrad Med; 1975 Sep; 58(3):217-221. PubMed ID: 27414711
[No Abstract] [Full Text] [Related]
53. A Serious Misapprehension.
Hayes T
Hospital (Lond 1886); 1912 Mar; 51(1338):569. PubMed ID: 29822884
[No Abstract] [Full Text] [Related]
54. Reliability of prisoners' survey responses: comparison of self-reported health and biomedical data from an australian prisoner cohort.
Butler TG; Gullotta M; Greenberg D
BMC Public Health; 2022 Jan; 22(1):64. PubMed ID: 35012501
[TBL] [Abstract][Full Text] [Related]
55. Hepatitis B vaccination coverage in Germany: systematic review.
Steffen G; Sperle I; Harder T; Sarma N; Beermann S; Thamm R; Bremer V; Zimmermann R; Dudareva S
BMC Infect Dis; 2021 Aug; 21(1):817. PubMed ID: 34391406
[TBL] [Abstract][Full Text] [Related]
56. Susceptibility to Hepatitis A and B Virus Among Clients at a Syringe Services Program in Philadelphia, 2018.
Figgatt M; Hildick-Smith J; Addish E; Coleman J; Benitez J; Freeland C; Alles S; Viner K; Johnson C; Kuncio D
Public Health Rep; 2020; 135(5):691-699. PubMed ID: 32791034
[TBL] [Abstract][Full Text] [Related]
57. Use of multiple data sources to estimate hepatitis C seroprevalence among prisoners: A retrospective cohort study.
Snow KJ; Richards AH; Kinner SA
PLoS One; 2017; 12(7):e0180646. PubMed ID: 28686715
[TBL] [Abstract][Full Text] [Related]
58. Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011-2013.
Brouard C; Pillonel J; Sogni P; Chollet A; Lazarus JV; Pascal X; Barin F; Jauffret-Roustide M;
Epidemiol Infect; 2017 Jan; 145(6):1-11. PubMed ID: 28100289
[TBL] [Abstract][Full Text] [Related]
59. Let It "B"? The role of Hepatitis B universal vaccination among italian problematic drug users.
Lugoboni F; Pavarin RM; Resentera C; Gambini D
Int J Environ Res Public Health; 2015 Apr; 12(4):3979-92. PubMed ID: 25872013
[TBL] [Abstract][Full Text] [Related]
60. Determinants of suboptimal hepatitis B vaccine uptake among men in the Republic of Korea: where should our efforts be focused: results from cross-sectional study.
Park B; Choi KS; Lee HY; Kwak MS; Jun JK; Park EC
BMC Infect Dis; 2013 May; 13():218. PubMed ID: 23672452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
